International Journal of Pharmaceutics, Год журнала: 2024, Номер unknown, С. 125053 - 125053
Опубликована: Дек. 1, 2024
Язык: Английский
International Journal of Pharmaceutics, Год журнала: 2024, Номер unknown, С. 125053 - 125053
Опубликована: Дек. 1, 2024
Язык: Английский
Smart Materials in Medicine, Год журнала: 2025, Номер unknown
Опубликована: Фев. 1, 2025
Язык: Английский
Процитировано
0Frontiers in Immunology, Год журнала: 2024, Номер 15
Опубликована: Окт. 8, 2024
Background T cell receptor (TCR)-T therapy is an innovative form of cancer immunotherapy that genetically modifies patients’ cells to target and destroy cells. However, the current status clinical trials TCR-T for treatment remains unclear. This study aimed comprehensively analyze registration related cancer. Methods A comprehensive search was conducted in Trialtrove database all registered by August 1, 2024. Inclusion criteria focused on targeting oncology, excluded observational studies incomplete data. Statistical analysis performed key trial characteristics, with between-group comparisons utilizing chi-square or Fisher’s exact tests. Results Analysis 174 eligible revealed exhibits significant efficacy across various tumor types, particularly refractory hematologic malignancies certain solid tumors. Additionally, combining other immunotherapies enhanced these anti-tumor effects. Conclusion holds substantial promise treatment. Future research should focus optimizing protocols, enhancing efficacy, minimizing prices fully realize potential this therapy.
Язык: Английский
Процитировано
2International Journal of Pharmaceutics, Год журнала: 2024, Номер unknown, С. 125053 - 125053
Опубликована: Дек. 1, 2024
Язык: Английский
Процитировано
0